Literature DB >> 34304732

French recommendations for the management of systemic sclerosis.

Eric Hachulla1, Christian Agard2, Yannick Allanore3, Jerome Avouac3, Brigitte Bader-Meunier4, Alexandre Belot5, Alice Berezne6, Anne-Sophie Bouthors7, Geraldine Condette-Wojtasik8, Joël Constans9, Pascal De Groote10, Elisabeth Diot11, Florence Dumas12, Patrick Jego13, Francisca Joly14, David Launay8, Veronique Le Guern15, Janine-Sophie Le Quintrec3, Geraldine Lescaille16, Christophe Meune17, Bruno Moulin18, Christelle Nguyen19, Nadine Omeish20, Frederic Pene21, Marie-Aleth Richard22, Juliette Rochefort20, Alexandra Roren23, Olivier Sitbon24, Vincent Sobanski8, Marie-Elise Truchetet25, Luc Mouthon26.   

Abstract

Systemic sclerosis (SSc) is a generalized disease of the connective tissue, arterioles, and microvessels, characterized by the appearance of fibrosis and vascular obliteration. There are two main phenotypical forms of SSc: a diffuse cutaneous form that extends towards the proximal region of the limbs and/or torso, and a limited cutaneous form where the cutaneous sclerosis only affects the extremities of the limbs (without passing beyond the elbows and knees). There also exists in less than 10% of cases forms that never involve the skin. This is called SSc sine scleroderma. The prognosis depends essentially on the occurrence of visceral damage and more particularly interstitial lung disease (which is sometimes severe), pulmonary arterial hypertension, or primary cardiac damage, which represent the three commonest causes of mortality in SSc. Another type of involvement with poor prognosis, scleroderma renal crisis, is rare (less than 5% of cases). Cutaneous extension is also an important parameter, with the diffuse cutaneous forms having less favorable prognosis.
© 2021. The Author(s).

Entities:  

Keywords:  Recommendations; Systemic sclerosis; Treatment

Mesh:

Year:  2021        PMID: 34304732      PMCID: PMC8310704          DOI: 10.1186/s13023-021-01844-y

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  94 in total

1.  Effect of orofacial exercises on oral aperture in adults with systemic sclerosis.

Authors:  Hon K Yuen; Nicole M Marlow; Susan G Reed; Samantha Mahoney; Lisa M Summerlin; Renata Leite; Elizabeth Slate; Richard M Silver
Journal:  Disabil Rehabil       Date:  2011-09-27       Impact factor: 3.033

2.  The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Ricardo J Bello; Carisa M Cooney; Eitan Melamed; Keith Follmar; Gayane Yenokyan; Gwendolyn Leatherman; Ami A Shah; Fredrick M Wigley; Laura K Hummers; Scott D Lifchez
Journal:  Arthritis Rheumatol       Date:  2017-06-26       Impact factor: 10.995

3.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

4.  Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Dinesh Khanna; Cathie Spino; Sindhu Johnson; Lorinda Chung; Michael L Whitfield; Christopher P Denton; Veronica Berrocal; Jennifer Franks; Bhavan Mehta; Jerry Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Anna Gill; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Elena Schiopu; Amber Young; Nora Sandorfi; Jane Park; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yue Wang; Tammara Wood; Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler; Ora Singer; Erica Bush; David A Fox; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

5.  The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study.

Authors:  Otylia Kowal-Bielecka; Sylwia Chwiesko-Minarowska; Pawel L Bernatowicz; Yannick Allanore; Timothy Radstake; Marco Matucci-Cerinic; Jasper Broen; Roger Hesselstrand; Dorota Krasowska; Gabriella Riemekasten; Madelon Vonk; Oksana Kowalczuk; Marek Bielecki; Robert Milewski; Lech Chyczewski; Jacek Niklinski; Krzysztof Kowal
Journal:  Rheumatology (Oxford)       Date:  2017-05-01       Impact factor: 7.580

Review 6.  Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.

Authors:  Dilia Giuggioli; Federica Lumetti; Michele Colaci; Poupak Fallahi; Alessandro Antonelli; Clodoveo Ferri
Journal:  Autoimmun Rev       Date:  2015-07-22       Impact factor: 9.754

7.  Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase.

Authors:  Susanna Maddali Bongi; Angela Del Rosso; Mauro Passalacqua; Sara Miccio; Marco Matucci Cerinic
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-08       Impact factor: 4.794

8.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

9.  Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients.

Authors:  L Teixeira; L Mouthon; A Mahr; A Berezné; C Agard; M Mehrenberger; L-H Noël; P Trolliet; C Frances; J Cabane; L Guillevin
Journal:  Ann Rheum Dis       Date:  2007-06-08       Impact factor: 19.103

10.  Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in systemic sclerosis.

Authors:  Susanna Maddali Bongi; Angela Del Rosso; Felice Galluccio; Fabrizio Sigismondi; Irene Miniati; M Letizia Conforti; Francesca Nacci; Marco Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2009-06-25       Impact factor: 2.980

View more
  2 in total

Review 1.  New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.

Authors:  Satoshi Ebata; Asako Yoshizaki-Ogawa; Shinichi Sato; Ayumi Yoshizaki
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

Review 2.  HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report.

Authors:  Shamimul Hasan; Mohd Aqil; Rajat Panigrahi
Journal:  Int J Environ Res Public Health       Date:  2022-08-15       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.